Journals / Mikrobiyoloji Bülteni / 2004 / Cilt: 38 - Sayı: 4

Clarithromycin resistance of Helicobacter pylori strains isolated from antral biopsy specimens

Antral biyopsi örneklerinden izole edilen Helicobacter pylori suşlarında Klaritromisin direnci

Pages
349–353
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The high rate of clarithromycin resistance among H.pylori strains in our study population, may give a direction to follow-up of the eradication therapy and to define regional treatment policies.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Helicobacter pylori is the main causative agent of peptic ulcer disease.
📊
Key Findings & Data:In this study, 78 H.pylori strains isolated from antral biopsy specimens of dyspeptic patients have been tested for susceptibility to clarithromycin, with NCCLS approved agar dilution and the E- test methods.
💡
Conclusion & Impact:The high rate of clarithromycin resistance among H.pylori strains in our study population, may give a direction to follow-up of the eradication therapy and to define regional treatment policies.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:İlaç direnci · Helicobacter pylori · Klaritromisin

Abstract

Helicobacter pylori is the main causative agent of peptic ulcer disease. Clarithromycin resistance in H.pylori is one of the common causes of failure of the eradication therapy based on the use of amoxicillin-clarithromycin and proton pomp inhibitors. In this study, 78 H.pylori strains isolated from antral biopsy specimens of dyspeptic patients have been tested for susceptibility to clarithromycin, with NCCLS approved agar dilution and the E- test methods. Sixteen (20.5%) of the strains were found resistant to clarithromycin, and the resistance rates were similar obtained by E-test and agar dilution method. The high rate of clarithromycin resistance among H.pylori strains in our study population, may give a direction to follow-up of the eradication therapy and to define regional treatment policies.

Özet

Helicobacter pylori peptik ülserin başlıca etiyolojik ajanıdır. Amoksisilin-klaritromisin ve proton pompa inhibitörlerinden oluşan H.pylori enfeksiyonunun eradikasyon tedavisinde, tedaviye yanıtı etkileyen en önemli faktör klaritromisin direncidir. Bu çalışmada dispeptik yakınmaları olan hastalardan alınan antral biyopsi örneklerinden izole edilen H.pylori suşlarında klaritromisin direnci E-test ve NCCLS standartlarına uygun olarak agar dilüsyon yöntemleriyle araştırılmıştır. Çalışılan 78 H.pylori izolatının 16'sında (%20.5) klaritromisine direnç tespit edilmiştir. E-test ve agar dilüsyon teknikleri karşılaştırıldığında benzer direnç oranları bulunduğu gözlenmiştir. Sonuç olarak, bölgemizde H.pylori izolatlarında yüksek direnç oranının saptanması, eradikasyon tedavisinin izlenmesi ve bölgesel tedavi protokollerinin belirlenmesi için yardımcı olacaktır kanısındayız.

🔖

Cite This Article

CAN, F., DEMİRBİLEK, M., SELÇUK, H., ARSLAN, H., BOYACIOĞLU, S. (2004). Clarithromycin resistance of Helicobacter pylori strains isolated from antral biopsy specimens. Mikrobiyoloji Bülteni, Cilt: 38 - Sayı: 4, 349–353. https://ajindex.com/articles/299865

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Warren JR, Marshall BJ: Unidentified curved bacili on gastric epıteilium in active chronic gastritis. Lancet 1983, i: 1273-1275
  2. Torres J, Camorlinga-Ponce M, Perez-Perez G: Increasing multidrug resistance in Helicobacter pylori strains isolated from children and adults in Mexico. J Clin Microbiol 2001, 39: 2677-2680
  3. Tankovic J, Lamarque D, Lascols C, Soussy C.J, Delchier JC: Clarithromycin resistance of Helicobacter pylori has a major impact on the efficiency of the omeprezole-amoxicillin-clarithromycin therapy. Pathol Biol 2001, 49: 528-533
  4. Sharara A, Chedid M. Araj G: Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin and tetracycline in Lebanon. Int J Antimic Agents 2002, 19: 155-158
  5. Kato M, Yamako Y, Kim J, et al: Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Antimicrob Agents Chemother 2000, 44: 2214-2216
  6. Glupczynski Y, Megraud F, Andersen LP: Antibiotic susceptibility of H.pylori in Europe in 1998: Results of the third multicentre study. Gut 1999, 45: A3
  7. Osato MS, Reddy R, Reddy SG: Comparison of the E-test and the NCCLS-approved agar dilution method to detect metronidazole and clarithromycin resistant Helicobacter pylori. Int J Antimicrob Agents 2001, 17: 39-44
  8. Osato MS, Reddy R, Graham DY Metronidazole and clarithromycin resistance amongst Helicobacter pylori isolates from a large metropolitan hospital in the United States. Int J Antimicrob Agents 1999, 12: 341-347
  9. Ademek RJ, Suerbaum S, Pfafenbach B, Opferkuch W: Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole and amoxicillin-intluence on treatment out-come. Am J Gastroenterol 1998, 93: 386-389
  10. Megraud F, Lehn N, Lind T: Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: The MACH 2 study. Antimicrobial Agents Chemother 1999, 43: 2747-2752
  11. Toracchio S, Marzıo L: Primary and secondary antibiotic resistance of Helicobacter pylori strains isolated in central Italy during the years 1998-2002. Digest Liver Dis 2003, 35: 541-545
  12. Us D, Hasçelik G: Seroprevalence of Helicobacter pylori in asymptomatic Turkish population J Infect 1998, 37: 148-150 13. Büke Ç, Aydın F, Günşar F ve ark. Helicobacter pylori'nin çeşitli antibiyotiklere karşı duyarlılığı Gastroenteroloji 1996, 7(ek1): 55
  13. Özçay F, Koçak N, Temizel INS ve ark: Helicobacter pylori infection